SCIENTIFIC PROGRAMME Saturday, 10 May 2025
012
Duration of ADHD medication treatment among Finnish children and adolescents: A nationwide register study Terhi Kolari, Finland M. Vuori, H. Rättö, E. Varimo, E. Aronen, K. Auranen, L. Saastamoinen, P. Ruokoniemi Benefits of methylphenidate treatment in children and adolescents with ADHD Vlatka Kovac, Croatia S. Jandric Beneficial effects of Pycnogenol® on ADHD: A review of clinical outcomes and mechanistic insights Barbara Luyens, Belgium I. Massat, F. Felgueroso-Bueno Q bCheck as an objective measure of ADHD symptoms to ensure optimal medical treat- ment in a paediatric population Sarah Moll, New Zealand C. Jardim, T. Marshall, C. Frampton, A. Ploeg, H. Barrow
006
Metabolic effects of pharmacological treat- ment options in a paediatric cohort of children and adolescences with ADHD: A real-world study Adriana Prato, Italy F. Saia, A. Longhitano, I. Pisani, R. Barone, R. Rizzo Enhanced neural gain: A mechanism for the amelioration of cognitive deficits by methyl- phenidate in ADHD? Protocol for a blinded, placebo-controlled study Declan Quinn, Ireland J. McGrath, R. Whelan, R. O’Connell, P. Murphy, E. O’Dea, B. Gavin, M. Shipsey, S. Ryan, M. Tsougkou, K. Haugh Treatment recommendation diversity and satisfaction in ADHD: Is TDApp an AI-based alternative to clinical practice guidelines? David Ramírez Saco, Spain E. Baykova, C. Lombardía, I. Andreu, D. Losada, T. Falkenhain, J. Risco, R. Cunill, Ò. Raya, B. López, X. Castells Cervelló
013
007
014
008
015
009
ADHD medication and Japan Saito Takuya, Japan
P-20 Guided Poster Tour 12:45 – 14:45 Pharmacological treatment III Chair: Ian Wong, Hong Kong 001
010
Comparative bioavailability of methylphe- nidate powder for prolonged-release oral suspension and methylphenidate prolonged- release chewable tablets versus methylpheni- date immediate-release tablets Alex Schneider-Pérez, Spain J. Ramos-Quiroga, M. Forcadell Ferré, M. Bouhajib Therapeutic equivalence of generic vs. origi- nal immediate-release methylphenidate in treating children with ADHD: A randomized crossover study Thanarat Suansanae, Thailand A. Sinrachatanant, B. Runglaksameesri, J. Jiamjaroenkul, T. Sirirutraykha, T. Tan-Khum Association of ADHD with Myopia among Hong Kong Children Jason Yam, Hong Kong X. Chen, X. Zhang, Y. Zhang, F. Tang, K. Kam, C. Tham, C. Pang, L. Chen, P. Ip, J. Yam Comparative effectiveness of second-line ADHD medications among children and ado- lescents using real world data: A target trial emulation study Le Zhang, Sweden N. Zhu, R. Kuja-Halkola, B. M. D’Onofrio, I. Brikell, P. Lichtenstein, H. Larsson, Z. Chang The promoting effects of digital targeted cog- nitive training in medication treatment for children with ADHD: A randomized controlled study Yu Zhu, People‘s Republic of China C. Dang, Y. Feng, G. Wu, S. Zhong, X. Luo, N. Shi, Y. Wang, L. Sun
Congress Hall Foyer 2B (2 nd Floor)
First-year MPH adherence: A data-driven guide to ADHD treatment selection Lilac Mosco, Israel Y. Bloch A ssessment of social functioning and callous- unemotional traits in children and adolescents with ADHD being treated with methylpheni- date: An observational study Chiara Narducci, Italy V. Scandurra, A. Fagiolini A ntipsychotic use in children and adolescents: Does ADHD diagnosis impact safety and pre- scription patterns? Inmaculada Palanca Maresca, Spain G. Centeno Soto, L. García Murillo, M. Jodar Gómez, J. Sánchez Cerezo, E. Baca-García, B. Ruiz-Antorán Objectifying the day-time response variation of (lis)dexamfetamine in adults with ADHD Esra Pirgon, The Netherlands R. Wettstein, G. Dumont H ow addictive is dexamfetamine?: A review of the literature Alison Poulton, Australia H. Khalifa, N. Gauci, E. Hibbert
011
002
012
003
013
004
005
014
34
Made with FlippingBook Digital Publishing Software